## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.9% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($331.98)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Cencora Moves To Take Full Control Of OneOncology**
- Source: Finimize | 20251215T160826 | Bullish | Relevance: 100%
- Cencora is acquiring nearly all of OneOncology for $5 billion, deepening its involvement in the growing US cancer care market. This move transitions Cencora from a minority to a controlling stake, aiming for long-term adjusted earnings growth despite initial neutrality. The deal signifies Cencora’s commitment to specialized healthcare and accelerates consolidation within the cancer care landscape.

**2. Cencora to buy majority of OneOncology's outstanding equity**
- Source: Axios | 20251215T160758 | Bullish | Relevance: 100%
- Cencora plans to acquire most of OneOncology's outstanding equity that it doesn't already own, including shares from TPG, for roughly $5 billion. This acquisition values the cancer practice network OneOncology at approximately $7.4 billion.

**3. Cencora stock price target raised to $420 from $400 at Evercore ISI**
- Source: Investing.com | 20251215T150826 | Bullish | Relevance: 100%
- Evercore ISI has increased its price target for Cencora Inc (NYSE:COR) to $420 from $400, maintaining an Outperform rating, following Cencora's strategic acquisition of the remaining stake in OneOncology. This move is seen as a "prudent use of capital" that is expected to be EPS neutral initially before contributing positively by mid-fiscal year 2027, leading to an upward revision of Cencora's long-term guidance. Other firms like TD Cowen, UBS, and Leerink Partners have also raised their price targets for Cencora, reflecting a positive analyst sentiment regarding the company's financial health, growth, and earnings potential.

**4. Cencora To Acquire Majority Stake in OneOncology From TPG**
- Source: citybiz | 20251215T140826 | Bullish | Relevance: 100%
- Cencora, Inc. announced its definitive agreement to acquire a majority stake in OneOncology from TPG for approximately $3.6 billion, in a transaction valuing OneOncology at $7.4 billion. This acquisition is expected to strengthen Cencora's specialty solutions, leverage OneOncology's market leadership in community-based oncology, and enhance patient access to pharmaceuticals. The deal, which also includes retiring $1.3 billion of OneOncology's debt, is anticipated to close by the end of Cencora’s fiscal 2026 second quarter and will be funded through new debt financing.

**5. Cencora, Inc. Agrees to Acquire Majority Stake in OneOncology**
- Source: TradingView — Track All Markets | 20251215T120813 | Bullish | Relevance: 100%
- Cencora, Inc. announced a $5 billion deal to acquire a majority stake in OneOncology, involving $3.6 billion for the company and retiring $1.3 billion in debt. The transaction, funded by $4.5 billion in new debt financing, is expected to close by fiscal 2026 Q2, pending regulatory approvals. This acquisition aligns with Cencora's growth strategy in specialty solutions and has led to a raise in their long-term guidance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $400 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.92 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $67.1B |
| Beta | 0.63 |
| 52W Range | $223.92 - $377.54 |
| Short Interest | 4.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.92 |
| Forward P/E | 17.7 |
| Current P/E | 19.6 |
| YoY Growth | 10.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -7.8% to -2.9% (+5.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 6.9pp (needs >4.0% for momentum thesis). MRS_5 turning positive (2.8%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.15x) but short-term weakness (below SMA20). MACD histogram bearish (-2.81), momentum weakening. RSI neutral at 48. OFD pattern: +SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.86% (CS: 16) | Weak |
| RSI_14 | 47.9 | Neutral |
| MACD Histogram | -2.81 | Bearish |
| vs SMA20 | 0.976x | Below |
| vs SMA50 | 1.012x | Above |
| vs SMA200 | 1.150x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $346.00
- **Stop Loss:** $331.98 (4.1% risk)
- **Target:** $360.02 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 71
- **Position Value:** $24,566.00
- **Portfolio %:** 24.57%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*